The study of sulphonylureas (glibenclamide) and GABA combined treatment on T1D mouse induced by STZ illustrated that, compared with monotherapy, combination treatment could remarkably improve glycemic control and enhance insulin secretion, which represents a promising anti-diabetic combination scheme (74). This evidence concerns the gene INS and type 1 diabetes mellitus.